Zhu Xiaowen, Hou Jinzhen, Zhang Qi, Wei Shujing, Cai Tianbin, Lyu Guangyu, Wang Xiaoyuan
Department of Critical Care Medicine, Liuzhou People's Hospital, Liuzhou 545006, Guangxi Zhuang Autonomous Region, China. Corresponding author: Zhu Xiaowen, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 May;33(5):517-522. doi: 10.3760/cma.j.cn121430-20200713-00515.
To investigate the effect of fluid resuscitation and circulatory support, directed by different target mean arterial pressure (MAP), on abdominal blood flow, gastrointestinal function and inflammatory response in septic shock patients with hypertension.
A prospective randomized controlled study was conducted. Hypertensive patients with septic shock admitted to the department of intensive care unit (ICU) of Liuzhou People's Hospital from January 1, 2019 to May 31, 2020 were enrolled. Patients were randomly divided into the low MAP groups (low standard group, LS group) or high MAP group (high standard group, HS group). According to the Surviving Sepsis Campaign Guidelines in 2016 and the updated guideline in 2018, all patients were given treatment of primary disease, fluid resuscitation, supportive management. The target MAP was 65-70 mmHg (1 mmHg = 0.133 kPa) in LS group, and was 75-80 mmHg in HS group. Acute gastrointestinal function injury (AGI) classification was performed on the 1st, 3rd and 7th day. The mean flow rate (Vm) and resistance index (RI) of superior mesenteric artery were evaluated using ultrasound, and the gastrointestinal function was dynamically evaluated using the modified single section ultrasonic gastric antrum method. The gastric antrum movement index (MI) and gastric empaging time (GET) were recorded. The levels of inflammatory markers in serum were detected by enzyme linked immunosorbent assay (ELISA), such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), procalcitonin (PCT) and vascular endothelial growth factor (VEGF). The target MAP, the days of use of vasopressors and the amount of fluid resuscitation were recorded.
A total of 208 hypertensive patients with septic shock were enrolled, including 109 in the LS group and 99 in the HS group. There were no significant differences in gender, age, acute physiology and chronic health evaluation II (APACHE II) score and sequential organ failure assessment (SOFA) score between the two groups when diagnosed. After treatment, there was no significant difference in AGI classification between the LS group and HS group on the 1st day. On the 3rd and 7th day, there were statistical differences between the two groups (3rd day: proportion of I, II, III, IV grades were 25.69%, 56.88%, 11.93%, 5.50% in LS group, 15.15%, 54.55%, 25.25%, 5.05% in HS group, respectively, χ = 7.900, P = 0.048; 7rd day: proportion of I, II, III, IV grades were 44.96%, 49.54%, 3.67%, 1.83% in LS group, 31.31%, 52.53%, 11.11%, 5.05% in HS group, respectively, χ = 8.178, P = 0.042). The Vm of superior mesenteric artery was higher and the RI was lower in the LS group than those in the HS group on day 1, 3 and 7 [Vm (cm/s): 21.72±3.02 vs. 19.50±2.83, 20.42±2.62 vs. 17.02±1.99, 26.52±2.70 vs. 22.47±4.03; RI: 0.86±0.05 vs. 0.92±0.04, 0.87±0.05 vs. 0.95±0.05, 0.81±0.03 vs. 0.85±0.03, all P < 0.01]. The MI was higher and the GET was shorter in the LS group than those in the HS group on day 3 and day 7 [MI: 3.00±0.33 vs. 2.60±0.29, 4.50±0.51 vs. 3.90±0.33; GET (minutes): 86.01±19.78 vs. 100.99±25.01, 71.00±16.37 vs. 84.98±20.18, all P < 0.01]. In addition, the levels of serum TNF-α, IL-6, PCT, VEGF were lower in the LS group than those in the HS group after 3 days of treatment [TNF-α (ng/L): 147.05±28.32 vs. 256.99±27.04, IL-6 (ng/L): 762.99±57.83 vs. 1 112.30±118.32, PCT (μg/L): 37.00±5.58 vs. 56.00±12.36, VEGF (ng/L): 123.00±19.78 vs. 167.01±21.55, all P < 0.05]. The target MAP was maintained at (68.02±4.71) mmHg in LS group, and (79.04±3.04) mmHg in HS group. The difference between the two groups was statistically significant (P < 0.01). Compared with the HS group, the days of using vasopressors was shorter in LS group (days: 3.50±1.27 vs. 4.55±1.47), and the amountof fluid was reduced significantly (mL: 1 602.29±275.49 vs. 2 000.30±272.59, both P < 0.01).
Maintaining a low target mean arterial pressure (65-70 mmHg) in hypertensive patients with septic shock can improve blood supply of superior mesenteric artery, protect the gastrointestinal function, reduce the level of inflammatory factors, and diminish the duration of using vasopressors and the amount of fluid.
探讨不同目标平均动脉压(MAP)指导下的液体复苏及循环支持对高血压合并感染性休克患者腹部血流、胃肠功能及炎症反应的影响。
进行一项前瞻性随机对照研究。纳入2019年1月1日至2020年5月31日在柳州市人民医院重症监护病房(ICU)收治的高血压合并感染性休克患者。将患者随机分为低MAP组(低标准组,LS组)和高MAP组(高标准组,HS组)。根据2016年《拯救脓毒症运动指南》及2018年更新指南,所有患者均给予原发疾病治疗、液体复苏、支持治疗。LS组目标MAP为65 - 70 mmHg(1 mmHg = 0.133 kPa),HS组目标MAP为75 - 80 mmHg。于第1、3、7天进行急性胃肠功能损伤(AGI)分级。采用超声评估肠系膜上动脉平均血流速度(Vm)和阻力指数(RI),采用改良单切面超声胃窦法动态评估胃肠功能。记录胃窦运动指数(MI)和胃排空时间(GET)。采用酶联免疫吸附测定(ELISA)法检测血清炎症标志物水平,如肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、降钙素原(PCT)和血管内皮生长因子(VEGF)。记录目标MAP、血管活性药物使用天数及液体复苏量。
共纳入208例高血压合并感染性休克患者,其中LS组109例,HS组99例。两组患者诊断时性别、年龄、急性生理与慢性健康状况评分系统II(APACHE II)评分及序贯器官衰竭评估(SOFA)评分比较,差异均无统计学意义。治疗后,第1天LS组与HS组AGI分级比较,差异无统计学意义。第3天和第7天,两组比较差异有统计学意义(第3天:LS组I、II、III、IV级比例分别为25.69%、56.88%、11.93%、5.50%,HS组分别为15.15%、54.55%、25.25%、5.05%,χ = 7.900,P = 0.048;第7天:LS组I、II、III、IV级比例分别为44.96%、49.54%、3.67%、1.83%,HS组分别为31.31%、52.53%、11.11%、5.05%,χ = 8.178,P = 0.042)。第1、3、7天,LS组肠系膜上动脉Vm高于HS组,RI低于HS组[Vm(cm/s):21.72±3.02比19.50±2.83,20.42±2.62比17.02±1.99,26.52±2.70比22.47±4.03;RI:0.86±0.05比0.92±0.04,0.87±0.05比0.95±0.05,0.81±0.03比0.85±0.03,均P < 0.01]。第3天和第7天,LS组MI高于HS组,GET短于HS组[MI:3.00±0.33比2.60±0.29,4.50±0.51比3.90±0.33;GET(分钟):86.01±19.78比100.99±25.01,71.00±16.37比84.98±20.18,均P < 0.01]。此外,治疗3天后,LS组血清TNF-α、IL-6、PCT、VEGF水平低于HS组[TNF-α(ng/L):147.05±28.32比256.99±27.04,IL-6(ng/L):762.99±57.83比1 112.30±118.32,PCT(μg/L):37.00±5.58比56.00±12.36,VEGF(ng/L):123.00±19.78比167.01±21.55,均P < 0.05]。LS组目标MAP维持在(68.02±4.71)mmHg,HS组维持在(79.04±3.04)mmHg。两组比较差异有统计学意义(P < 0.01)。与HS组比较,LS组血管活性药物使用天数短(天数:3.50±1.27比4.55±1.47),液体量显著减少(mL:1 602.29±275.49比2 000.30±272.59,均P < 0.01)。
高血压合并感染性休克患者维持较低目标平均动脉压(65 - 70 mmHg)可改善肠系膜上动脉供血,保护胃肠功能,降低炎症因子水平,减少血管活性药物使用时间及液体量。